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Background: The aim of this study was to analyze the clinical characteristics of patients with 
adverse cutaneous drug reactions, which occur when a medicinal product results in cutaneous 
morbidity.
Methods: The study included 308 patients who were diagnosed as having an adverse cutaneous 
drug reaction during the study period (2007–2009). In 84 cases, histopathologic examination 
of skin biopsies were also performed.
Results: Patients with drug reactions were found to be more commonly female (63%) than male 
(37%). Beta-lactam antibiotics were found to be the most frequent cause of adverse cutaneous 
drug reactions (42.7%), followed by non-steroidal anti-inflammatory drugs (16.5%). Acute 
urticaria was the most common clinical presentation (59.2%) followed by fixed drug eruptions 
(18.5%), and maculopapular eruptions (14.9%).
Conclusion: Adverse cutaneous drug reactions in our study population were mainly induced 
by beta-lactam antibiotics and non-steroidal anti-inflammatory drugs. The most common forms 
of cutaneous adverse drug reactions were found to be acute urticaria, fixed drug eruptions, and 
maculopapular rashes.
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Introduction
Adverse drug reactions (ADRs) are undesirable and typically unanticipated reactions 
independent of the intended therapeutic purpose of a medication,1 that may result in 
significant morbidity and even mortality. Cutaneous reactions are the most common 
form of ADRs,2 occurring in 2%–3% of inpatient and in approximately 2% of outpa-
tient patients referred for dermatologic evaluation; approximately 2% of ADRs are 
considered severe or fatal.3,4 Drug reactions are more common in women, and increase 
with age and the number of medications used.5
ADRs may be either immunologic (ie, drug allergy) or non-immunologic (ie, drug 
intolerance), with drug allergies estimated to account for 6%–10% of all ADRs, and 
drug intolerance accounting for the remaining 90%–94%.6 Cutaneous ADRs produce 
a wide range of clinical manifestations such as pruritus, maculopapular eruptions, 
urticaria, angioedema, phototoxic and photo allergic reactions, fixed drug reactions, 
erythema multiforme, vesiculobullous reactions (eg, Stevens–Johnson syndrome and 
toxic epidermal necrolysis), exfoliative dermatitis, acute generalized exanthematous 
pustulosis, and serum sickness.7,8 Whereas maculopapular rashes and urticaria are 
among the most common cutaneous drug reactions,9 anaphylaxis, Stevens–Johnson 
syndrome, and toxic epidermal necrolysis may result in mortality.10
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The purpose of this study was to examine the clinical 
characteristics and purported etiologic agents for ADRs in 
our patient population.
Materials and methods
A descriptive, prospective case-series study was performed 
during 2007–2009. Three hundred and eight consecu-
tive inpatient and outpatient subjects with a diagnosis of 
ADR referred to the dermatology service of Sina hospital 
in Hamadan, Iran were enrolled in the study. All patients 
suspected of having an ADR were clinically evaluated by 
an attending dermatologist. In 84 cases, histopathological 
examination of skin biopsies were obtained, in many cases 
to distinguish between specific types of drug reaction, eg, 
DRESS syndrome versus exanthematous eruptions. The 
presence of eosinophils in dermal inflammatory infiltrates 
was considered to support a hypersensitivity reaction.
Each patient was informed of the nature of the study and 
signed a consent form approved by the Research Council 
and Ethics Committee of Hamedan University of Medical 
Sciences, Hamedan, Iran. Written informed consent was 
obtained from patients for publication of this study and 
for any accompanying images. The study was performed 
in accordance with the ethical guidelines of the 1975 
Declaration of Helsinki.
Exclusion criteria in this study included: 1) a history of 
taking more than one drug class likely to cause the adverse 
reaction; 2) clinical manifestations that were not compatible 
with drug reactions; 3) patient inability to produce the medi-
cation consumed the last 3 weeks that purportedly caused the 
reaction (to prevent recall bias); 4) cases involving overlap-
ping diagnoses with other conditions; and 5) cases in which 
the clinical diagnosis did not match the findings cited in the 
pathology report.
Results
During the study period, 308 patients, including 114 men (37%) 
and 194 women (63%), were enrolled. Of the 308 patients, 
the diagnosis of ADR was made based on purely clini-
cal manifestations in 224 cases; histological confirmation 
was obtained in 84 cases. The mean age of patients was 
35.2±16.8 years (range 2–77 years). In the present study, 
ADRs were more frequently seen in the third and fourth 
decades of life, with 40% of reactions seen in this age group. 
The clinical manifestations of cutaneous ADRs are summa-
rized in Table 1 and examples are provided in Figures 1 and 2. 
Only 20 of the 308 patients (6.5%) in our study reported a 
history of a previous drug reactions.
In patients with urticarial drug eruptions, 76 (46.6%) were 
attributed to antibiotics, 45 (27.4%) to non-steroidal anti-
inflammatory drugs (NSAIDs), and 17 (10.4%) to codeine 
with acetaminophen. In patients with maculopapular erup-
tions, 21 (45.6%) were attributed to antibiotic use, 12 (26%) 
to anticonvulsant drugs, and four (8.6%) to NSAIDs. In the 
beta-lactam and NSAID subgroups, amoxicillin and ibupro-
fen were the most common offending agents, respectively. In 
patients with fixed drug eruptions, 34 (59.6%) were attributed 
to taking trimethoprim-sulfamethoxazole and nine (15.7%) 
to taking NSAIDs (Figure 3).
In patients with a diagnosis of fixed drug eruption 
induced by trimethoprim-sulfamethoxazole (34 patients), 
most lesions were present in the genital area (18 patients). 
Five patients had lesions in both the genital area and the lip, 
and only one patient suffered from a lesion present only on 
the lip. The remaining patients had lesions in other areas, 
Figure 1 a 25-year-old woman with the diagnosis of acute generalized exanthematous 
pustulosis following the use of cephalexin.
Table 1 Clinical manifestations of cutaneous adverse drug reactions
Clinical feature n % Number of patients 
histologically confirmed
acute urticaria 163 52.9 4
Fixed drug eruption 57 18.5 30
exanthematous eruption 46 14.9 18
erythema multiforme 7 2.3 7
acute generalized  
exanthematous pustulosis
7 2.3 7
Vasculitis 7 2.3 7
angioedema 7 2.3 –
erythroderma 4 1.3 4
stevens–Johnson syndrome 3 1 3
serum sickness 3 1 0
exfoliative dermatitis 2 0.6 2
Dress syndrome 1 0.3 1
Photosensitive dermatitis 1 0.3 1
Total 308 100 84
Abbreviation: Dress, Drug reaction with eosinophilia and systemic symptoms.
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including the hands and feet. In the group taking NSAIDs 
(nine patients), one patient had a fixed drug eruption on the 
lip, one patient had it on the genital area, and two patients 
had lesions on both the lip and genital area. The remaining 
five patients had lesions on other body areas, including the 
hands, feet, and trunk.
Among the seven patients with erythema multiforme, two 
had history of taking trimethoprim-sulfamethoxazole. In this 
study, only one patient had a diagnosis of DRESS syndrome, 
which was attributed to phenytoin.
In this study, the most common cutaneous clinical mani-
festations of ADRs in the order of frequency were urticaria, 
maculopapular eruptions, and fixed drug reactions (Table 1). 
Antibiotics (42.7%) and NSAIDs (16.5%) were the most 
common causes of drug reactions in our study population.
Discussion
Consistent with the results of previous studies, we found that 
adverse cutaneous drug reactions are more common in women 
than in men.11 In the present study, 40% of drug reactions were 
Figure 2 a 37-year-old woman with clinical manifestation of Dress syndrome due 
to phenytoin.
Abbreviation: Dress, Drug reaction with eosinophilia and systemic symptoms.
Drug-induced urticaria
15.6%
10.4%
27.4%
24.7%
15.7%
59.6%
Antibiotics
NSAIDs
Other drugs
Anticonvulsant drugs
Acetaminophen/codeine
46.6%
26%
8.6%
45.6%
19.8%
Fixed drug eruption
Maculopapular eruptions
Figure 3 Causative agents for the three most common types of cutaneous drug reactions: urticaria, fixed drug eruptions, and maculopapular eruptions.
Abbreviation: NSAIDs, non-steroidal anti-inflammatory drugs.
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seen in third and fourth decades of life, which is consistent 
with the findings of Sushma et al in their 2005 study.8
In the study performed by Souissi et al in 2007, the most 
common cutaneous clinical manifestations were maculopapu-
lar eruptions followed by fixed drug eruptions, and antibiotics 
and NSAIDs were the most commonly purported agents.12 
Fiszenson-Albala et al, in a study of drug reactions in the 
French population, reported maculopapular eruptions fol-
lowed by urticaria and erythroderma to be the most frequent 
ADRs in their population.13 Kacalak-Rzepka et al reported 
maculopapular eruptions and urticaria as the most common 
forms of ADR.11 The high prevalence of urticaria in our study 
may be due to the excessive use of beta-lactam antibiotics 
for the treatment of upper respiratory viral infections, often 
without proper medical indication.
In patients with a diagnosis of fixed drug eruption induced 
by trimethoprim-sulfamethoxazole, most lesions were seen 
in the genital area, whereas in the group taking NSAIDs, 
most lesions were seen on the hands and feet. In comparison, 
Justiniano et al reported that fixed drug eruptions induced 
by trimethoprim-sulfamethoxazole were most commonly 
present on the genital area, while those induced by NSAIDs 
were most commonly seen on the lip.14
It should be noted that our study does not address the 
mechanism of ADRs, and many drug reactions may not result 
from allergic or non-allergic drug hypersensitivity. In addition, 
a drug reaction cannot be confirmed without further testing, 
such as rechallenge, which was not performed in our study. 
Moreover, histologic examination may not reveal changes 
specific to a drug eruption, although biopsies may be helpful 
in distinguishing particular subtypes of reactions. Furthermore, 
a more helpful study may compare the adverse event rate to 
exposure rate by gathering local data on dispensing of various 
etiologic agents to estimate the cutaneous adverse event rate.
Conclusion
According to our results, adverse cutaneous drug reactions 
were mainly induced by beta-lactam antibiotics and NSAIDs. 
The most common forms of cutaneous ADRs in order of 
frequency were acute urticaria, fixed drug eruptions, and 
maculopapular rashes. In our study, the most common form 
of cutaneous ADR was found to be urticaria, while some 
studies conducted in other parts of the world have found 
maculopapular eruptions to be more common. The high 
consumption of beta-lactam antibiotics in the treatment 
of common viral upper respiratory infections in our area may 
contribute to our findings.
Disclosure
The authors have no conflicts of interest to declare.
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